Allarity Therapeutics (ALLR) Stock Price, News & Analysis

Company Overview

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $0.89 to $0.93
• 50-Day Range: $0.80 to $1.20
• 52-Week Range: $0.61 to $10.59
• Volume: 321,131 shs
• Average Volume: 1.12 million shs
• Market Capitalization: $13.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALLR Stock Analysis - Frequently Asked Questions

How have ALLR shares performed this year?

Allarity Therapeutics' stock was trading at $1.17 at the beginning of the year. Since then, ALLR shares have decreased by 23.1% and is now trading at $0.90.
View the best growth stocks for 2025 here.

How were Allarity Therapeutics' earnings last quarter?

Allarity Therapeutics, Inc. (NASDAQ:ALLR) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($8.10) by $7.85.

When did Allarity Therapeutics' stock split?

Allarity Therapeutics shares reverse split on the morning of Wednesday, September 11th 2024.The 1-30 reverse split was announced on Wednesday, September 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How will Allarity Therapeutics' stock buyback program work?

Allarity Therapeutics' Board of Directors authorized a stock buyback plan on Monday, March 3rd 2025, which authorizes the company to buy back $5,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 128.1% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its stock is undervalued.

How do I buy shares of Allarity Therapeutics?

Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Allarity Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allarity Therapeutics investors own include AMC Entertainment (AMC), Plug Power (PLUG), Adial Pharmaceuticals (ADIL), Cara Therapeutics (CARA), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH) and Nuwellis (NUWE).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/23/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALLR
• CIK: 1860657
• Web: www.allarity.com
• Phone: 401-426-4664
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.51 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -147.94%
• Return on Assets: -90.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.66
• Quick Ratio: 2.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.62 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 15,080,000
• Free Float: 15,078,000
• Market Cap: $13.57 million
• Optionable: Not Optionable
• Beta: -0.15